Figure S8 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

This is a Experimental Study study.

Key Points

The treatment strategy shows improved outcomes in pancreatic cancer models with MTAP deletion and KRAS mutations.
Utilizing the combination of PRMT5 inhibitors and KRAS inhibitors demonstrates a significant effect on cell viability.
GSEA analysis reveals changes in cell signaling pathways when treated with PRMT5 inhibitors and KRAS inhibitors.
These findings may enhance therapeutic approaches for difficult-to-treat pancreatic cancer cases.

We only have this paper's title and publication details.

Combination therapy reduces tumor growth in pancreatic cancer cells with MTAP deletion, highlighting KRAS inhibitors' role.

Figure S8 shows GSEA of PRMT5i- and G12Di-treated cells.

No takes yet. Share an insight, caveat, or question.

Drizyte‐Miller et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share